DIN 02312441 — PRADAXA 110 MG
PRADAXA is a capsule of Dabigatran Etexilate marketed by BOEHRINGER INGELHEIM (CANADA) LTD LTEE. The full Dabigatran Etexilate monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02312441
- Brand name
- PRADAXA
- Active ingredient
- Dabigatran Etexilate
- Strength
- 110 MG
- Dosage form
- CAPSULE
- Route
- ORAL
- Manufacturer
- BOEHRINGER INGELHEIM (CANADA) LTD LTEE
- Health Canada status
- MARKETED
- Drug class
- Direct thrombin inhibitor (anticoagulant)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Dabigatran Etexilate products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02468905 | APO-DABIGATRAN | 110 MG | CAPSULE | APOTEX INC | MARKETED |
| 02468913 | APO-DABIGATRAN | 150 MG | CAPSULE | APOTEX INC | MARKETED |
| 02468891 | APO-DABIGATRAN | 75 MG | CAPSULE | APOTEX INC | MARKETED |
| 02358808 | PRADAXA | 150 MG | CAPSULE | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED |